U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495995) titled 'Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis' on March 22.
Brief Summary: This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. Investigators will assess whether treatment is associated with changes in liver-related clinical measures, biologic markers, and other study outcomes relevant to disease progression. The goal of this study is to generate early data to determine whether SAMe should be studied further as...